← back to search

Lisa Hopcroft

University of Glasgow · GB
Area of research
Infectious Diseases · Hematology
Research interest
Research interests include Chronic Myeloid Leukemia Treatments, COVID-19 Clinical Research Studies, COVID-19 Impact on Reproduction, and COVID-19 and healthcare impacts.
h-index
24
citations
2,501
works
113
NIH funding
primary concept
Medicine
email

Recent publications

Outpatient hospital attendances in people with rheumatoid arthritis during the COVID-19 pandemic and beyond: a cohort study in three nations of the UK
Lara D. Veeken 2025cited by 0position: middledoi
Impact of long COVID on health-related quality-of-life: an OpenSAFELY population cohort study using patient-reported outcome measures (OpenPROMPT)
The Lancet Regional Health - Europe 2024cited by 94position: middledoi
Impact of vaccination on the association of COVID-19 with cardiovascular diseases: An OpenSAFELY cohort study
Nature Communications 2024cited by 37position: middledoi
Clinical coding of long COVID in primary care 2020–2023 in a cohort of 19 million adults: an OpenSAFELY analysis
EClinicalMedicine 2024cited by 23position: middledoi
Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people
The Lancet Diabetes & Endocrinology 2024cited by 21position: middledoi
Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche
Nature Communications 2024cited by 6position: middledoi
Impact of COVID-19 on recorded blood pressure screening and hypertension management in England: an analysis of monthly changes in the quality and outcomes framework indicators in OpenSAFELY
Open Heart 2024cited by 5position: middledoi
OpenSAFELY: The impact of COVID‐19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate
British Journal of Clinical Pharmacology 2024cited by 2position: middledoi
A population-based matched cohort study of major congenital anomalies following COVID-19 vaccination and SARS-CoV-2 infection
Nature Communications 2023cited by 39position: middledoi
Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY
BMJ Medicine 2023cited by 37position: middledoi
Neonatal and maternal outcomes following SARS-CoV-2 infection and COVID-19 vaccination: a population-based matched cohort study
Nature Communications 2023cited by 33position: middledoi
Ethnic differences in the indirect effects of the COVID-19 pandemic on clinical monitoring and hospitalisations for non-COVID conditions in England: a population-based, observational cohort study using the OpenSAFELY platform
EClinicalMedicine 2023cited by 6position: middledoi
Pregnancy outcomes after SARS-CoV-2 infection in periods dominated by delta and omicron variants in Scotland: a population-based cohort study
The Lancet Respiratory Medicine 2022cited by 77position: middledoi
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)
British Journal of Cancer 2022cited by 65position: middledoi
Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records
BMJ 2022cited by 62position: middledoi
A population-based matched cohort study of early pregnancy outcomes following COVID-19 vaccination and SARS-CoV-2 infection
Nature Communications 2022cited by 40position: middledoi
Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY
BMC Medicine 2022cited by 29position: middledoi
Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia
Nature Medicine 2018cited by 162position: middledoi
hsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survival
Blood 2018cited by 46position: middledoi
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells
Blood 2016cited by 108position: middledoi
Systems Genetics
Cambridge University Press eBooks 2015cited by 5position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Clara Calvert · Centre for Global Health Research3 papers (2022–2023)Sarah J. Stock · Trinity College Dublin3 papers (2022–2023)Jack Donaghy · Public Health Scotland3 papers (2022–2023)Terry McLaughlin · Public Health Scotland3 papers (2022–2023)Jade Carruthers · Public Health Scotland3 papers (2022–2023)Cheryl Denny · Public Health Scotland3 papers (2022–2023) · 3 papers (2022–2023)Chris Robertson · University of Strathclyde3 papers (2022–2023)Srinivasa Vittal Katikireddi · MRC/CSO Social and Public Health Sciences Unit3 papers (2022–2023)Anna Goulding · Public Health Scotland3 papers (2022–2023)Aziz Sheikh · National Institute of Technology Srinagar3 papers (2022–2023)Colin R Simpson · Victoria University of Wellington3 papers (2022–2023)Rachael Wood · University of Canterbury3 papers (2022–2023)Leanne Hopkins · Public Health Scotland3 papers (2022–2023)Emily Moore · University of Technology Sydney3 papers (2022–2023)Tessa L. Holyoake · University of Glasgow2 papers (2016–2018)J. R. Taylor · Public Health Scotland2 papers (2023–2023)Colin McCowan · St. Andrews University2 papers (2022–2023)Ravi Bhatia · Pediatric Nephrology of Alabama2 papers (2016–2018)Ting Shi · Guangzhou University of Chinese Medicine2 papers (2023–2023)